How I treat paroxysmal nocturnal hemoglobinuria

Research output: Contribution to journalArticle

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal blood disorder that manifests with hemolytic anemia, bone marrow failure, and thrombosis. Many of the clinical manifestations of the disease result from complement-mediated intravascular hemolysis. Allogeneic bone marrow transplantation is the only curative therapy for PNH. Eculizumab, a monoclonal antibody that blocks terminal complement activation, is highly effective in reducing hemolysis, improving quality of life, and reducing the risk for thrombosis in PNH patients. Insights into the relevance of detecting PNH cells in PNH and other bone marrow failure disorders are highlighted, and indications for treating PNH patients with bone marrow transplantation and eculizumab are explored.

Original languageEnglish (US)
Pages (from-to)6522-6527
Number of pages6
JournalBlood
Volume113
Issue number26
DOIs
StatePublished - 2009

Fingerprint

Paroxysmal Hemoglobinuria
Bone
Hemolysis
Bone Marrow Transplantation
Thrombosis
Bone Marrow
Blood
Complement Activation
Chemical activation
Hemolytic Anemia
Homologous Transplantation
Monoclonal Antibodies
Quality of Life
eculizumab

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

How I treat paroxysmal nocturnal hemoglobinuria. / Brodsky, Robert A.

In: Blood, Vol. 113, No. 26, 2009, p. 6522-6527.

Research output: Contribution to journalArticle

Brodsky, Robert A. / How I treat paroxysmal nocturnal hemoglobinuria. In: Blood. 2009 ; Vol. 113, No. 26. pp. 6522-6527.
@article{0e6ac54a90bf436595538c38e8d2b12b,
title = "How I treat paroxysmal nocturnal hemoglobinuria",
abstract = "Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal blood disorder that manifests with hemolytic anemia, bone marrow failure, and thrombosis. Many of the clinical manifestations of the disease result from complement-mediated intravascular hemolysis. Allogeneic bone marrow transplantation is the only curative therapy for PNH. Eculizumab, a monoclonal antibody that blocks terminal complement activation, is highly effective in reducing hemolysis, improving quality of life, and reducing the risk for thrombosis in PNH patients. Insights into the relevance of detecting PNH cells in PNH and other bone marrow failure disorders are highlighted, and indications for treating PNH patients with bone marrow transplantation and eculizumab are explored.",
author = "Brodsky, {Robert A}",
year = "2009",
doi = "10.1182/blood-2009-03-195966",
language = "English (US)",
volume = "113",
pages = "6522--6527",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "26",

}

TY - JOUR

T1 - How I treat paroxysmal nocturnal hemoglobinuria

AU - Brodsky, Robert A

PY - 2009

Y1 - 2009

N2 - Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal blood disorder that manifests with hemolytic anemia, bone marrow failure, and thrombosis. Many of the clinical manifestations of the disease result from complement-mediated intravascular hemolysis. Allogeneic bone marrow transplantation is the only curative therapy for PNH. Eculizumab, a monoclonal antibody that blocks terminal complement activation, is highly effective in reducing hemolysis, improving quality of life, and reducing the risk for thrombosis in PNH patients. Insights into the relevance of detecting PNH cells in PNH and other bone marrow failure disorders are highlighted, and indications for treating PNH patients with bone marrow transplantation and eculizumab are explored.

AB - Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal blood disorder that manifests with hemolytic anemia, bone marrow failure, and thrombosis. Many of the clinical manifestations of the disease result from complement-mediated intravascular hemolysis. Allogeneic bone marrow transplantation is the only curative therapy for PNH. Eculizumab, a monoclonal antibody that blocks terminal complement activation, is highly effective in reducing hemolysis, improving quality of life, and reducing the risk for thrombosis in PNH patients. Insights into the relevance of detecting PNH cells in PNH and other bone marrow failure disorders are highlighted, and indications for treating PNH patients with bone marrow transplantation and eculizumab are explored.

UR - http://www.scopus.com/inward/record.url?scp=69249221393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249221393&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-03-195966

DO - 10.1182/blood-2009-03-195966

M3 - Article

C2 - 19372253

AN - SCOPUS:69249221393

VL - 113

SP - 6522

EP - 6527

JO - Blood

JF - Blood

SN - 0006-4971

IS - 26

ER -